Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
Sizing up Straumann Holding after recent share performance
Straumann Holding (SWX:STMN) has been in focus after recent share performance, with the stock showing a 4.4% decline over the past month and a modest gain over the past 3 months.
For investors tracking longer horizons, total returns are currently negative over the past year and past 3 years, while the past 5 years also reflect a decline, which sets a cautious backdrop for any fresh review.
See our latest analysis for Straumann Holding.
The 1 day share price return of a 0.43% decline and 7 day share price return of a 2.66% decline, alongside a 1 year total shareholder return of a 23.94% decline, point to fading momentum despite a slightly positive 90 day share price return.
If this weaker recent share price trend has you reassessing where you put fresh capital, it could be a good time to widen your search and look at 115 healthcare AI stocks as a way to find other potential opportunities in the broader health related space.
With Straumann trading at CHF 92.36 and sitting at an estimated 25% discount to one intrinsic value estimate and 17% below one analyst target, is this pricing in enough future growth, or is the market already calling it fair value?
Most Popular Narrative: 17% Undervalued
On the most followed narrative, Straumann Holding's fair value sits at about CHF111 per share, compared with the latest close at CHF92.36. This sets up a valuation gap that hinges on execution in growth areas and margins.
Ongoing expansion in digital dentistry, evidenced by double digit growth in intraoral scanners and 3D printing solutions, is positioning Straumann to benefit from structural industry shifts toward integrated digital workflows. This is expected to drive recurring higher margin revenues and operating leverage over time. (Impacts: recurring revenues, net margins, long term earnings)
Curious how that growth story translates into the CHF111 fair value figure? The narrative leans heavily on steady top line expansion, rising profitability and a future earnings multiple that assumes investors continue to pay a premium for that profile. The exact mix of revenue growth, margin improvement and valuation multiple assumptions might surprise you.
Result: Fair Value of CHF111 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside story could unravel if currency headwinds persist, or if price pressure and underperformance in China and orthodontics weigh more heavily on margins and growth expectations.
Find out about the key risks to this Straumann Holding narrative.
Another View: Multiples Point to a Very Different Story
While the SWS DCF model suggests Straumann is trading below estimated fair value, the market is pricing the shares on a rich P/E of 41.3x. That is above both the peer average of 30.4x and the fair ratio of 39.2x, which implies less room for error if growth or margins disappoint.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals on value and risks so far? Take a moment to look through the numbers yourself, weigh the trade offs, and check out 2 key rewards and 1 important warning sign to round out your view.
Ready to hunt for more investment ideas?
If this review has sharpened your thinking, do not stop here. Use the screener to line up your next few watchlist candidates while everything is fresh.
-
Target reliability first by scanning companies in our 324 resilient stocks with low risk scores that focus on resilience and lower overall risk scores.
-
Spot potential value by checking screener containing 571 high quality undiscovered gems , a collection of lesser known names with solid underlying fundamentals.
-
Prioritise balance sheet strength by reviewing the solid balance sheet and fundamentals stocks screener (370 results) that highlights businesses with financial structures designed to handle tougher conditions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include STMN.SW .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
